CONFERENCE

"Recent Disclosures of Clinical Candidates and SMR Award Lecture"

1st December 2016
NHLI, South Kensington, London, UK

Registration fee:
Members: £85
Non-members: £135
Special event rate
including Membership: £110

PROGRAMME OF SPEAKERS:

2016 SMR Award Lecture & Presentation:

The 2016 SMR Award winner is Opdivo® (nivolumab) – an anti-programmed death receptor-1 (PD-1) antibody approved to treat several cancers

Dr Francis Cuss, Bristol-Myers Squibb
"The discovery, development and delivery of Opdivo"

Dr. Barnard Barlaam, AstraZeneca
'Identifying high quality, potent and selective inhibitors of ATM kinase for oncology therapies: Discovery of AZD0156'

Dr Thomas Fuchss, Merck KGaA
'Highly potent and selective DNA-PK inhibitor M3814 with sustainable anti-tumour activity in combination with radiotherapy'

Dr. David Edwards, Cancer Research UK
'A different class of oncology therapeutic: development of MOv18 – a novel IgE-based therapeutic targeting folate receptor alpha'

Dr. Sandrine Vendeville, Tibotec J&J Belgium
'Discovery of the clinical candidate JNJ-53718678, a potent and orally bioavailable fusion inhibitor of Respiratory Syncytial Virus'

Dr. John Liddle, GSK
'Recent disclosure of a kynurenine 3-monooxygenase inhibitor as development candidate to treat severe acute pancreatitis - a drug discovery partnership between GSK and The University of Edinburgh'

Dr. Nick Clarke, Pfizer
'Out with the old indication, bring in the new clinical compound for sickle cell disease'

Follow us on:

Student bursaries are available
Please see our web site or contact the Secretariat.

Follow us on:

To view meeting abstracts and to register on-line please visit:

www.smr.org.uk

Or alternatively, contact the SMR Secretariat at:
Unit Q, Troon Way Business Centre, Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 2747356 Fax: 0116 2747365 Email: **secretariat@smr.org.uk**